Patents by Inventor Jurgen KLAR

Jurgen KLAR has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230065629
    Abstract: The present invention covers substituted 6-(1H-pyrazol-1-yl)pyrimidin-4-amine compounds of general formula (I) as described and defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds, and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular for the treatment and/or prophylaxis of cardiovascular and renal diseases, as a sole agent or in combination with other active ingredients.
    Type: Application
    Filed: November 4, 2021
    Publication date: March 2, 2023
    Applicants: Bayer Aktiengesellschaft, Bayer Pharma Aktiengesellschaft
    Inventors: Anja GIESE, Jürgen KLAR, Alexander Helmut Michael EHRMANN, Jens WILLWACHER, David ENGEL, Andre Philippe DIESKAU, Antje KAHNERT, Alexey GROMOV, Carsten SCHMECK, Niels LINDNER, Thomas MÜLLER, Anna Lena ANDREEVSKI, Jan DREHER, Karl COLLINS
  • Publication number: 20230053411
    Abstract: The present invention relates to 1,3-thiazol-2-yl substituted benzamide compounds of general formula (I) as described and defined herein, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of neurogenic disorder, as a sole agent or in combination with other active ingredients.
    Type: Application
    Filed: September 9, 2021
    Publication date: February 23, 2023
    Applicant: Bayer Aktiengesellschaft
    Inventors: Adam James DAVENPORT, Nico BRÄUER, Oliver Martin FISCHER, Andrea ROTGERI, Antje ROTTMANN, Ioana NEAGOE, Jens NAGEL, Anne-Marie GODINHO-COELHO, Jürgen KLAR
  • Publication number: 20230027985
    Abstract: The application relates to substituted hydantoinamides of formula (I) as ADAMTS7 antagonists, to processes for their preparation, their use alone or in combination for the treatment or prophylaxis of diseases, in particular of cardiovascular diseases, including atherosclerosis, coronary artery disease (CAD), peripheral vascular disease (PAD), arterial occlusive disease or restenosis after angioplasty. R1 is hydrogen, alkyl, cycloalkyl, heterocycloalkyl, 5- to 6-membered heteroaryl or phenyl; R2 is hydrogen or alkyl; A is 5-membered heteroaryl; Z is 6- to 10-membered aryl or 5- to 10-membered heteroaryl; all groups being optionally substituted.
    Type: Application
    Filed: November 12, 2020
    Publication date: January 26, 2023
    Applicants: Bayer Aktiengesellschaft, The Broad Institute, Inc.
    Inventors: Daniel MEIBOM, Yolanda CANCHO GRANDE, Pierre WASNAIRE, Sarah Anna Liesa JOHANNES, Niels LINDNER, Kristin BEYER, Till FREUDENBERGER, Damian BROCKSCHNIEDER, Ilka MATHAR, Jürgen KLAR, Dmitry ZUBOV, Dzianis MENSHYKAU, Tanja KRAINZ, Eric STEFAN, Bryan MACDONALD, Yi XING, Nadine ELOWE, Guzman SANCHEZ
  • Patent number: 11208400
    Abstract: The present invention covers substituted 6-(1H-pyrazol-1-yl)pyrimidin-4-amine compounds of general formula (I) as described and defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds, and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular for the treatment and/or prophylaxis of cardiovascular and renal diseases, as a sole agent or in combination with other active ingredients.
    Type: Grant
    Filed: October 9, 2017
    Date of Patent: December 28, 2021
    Assignees: Bayer Aktiengesellschaft, Bayer Pharma Aktiengesellschaft
    Inventors: Anja Giese, Jürgen Klar, Alexander Helmut Michael Ehrmann, Jens Willwacher, David Engel, Andre Philippe Dieskau, Antje Kahnert, Alexey Gromov, Carsten Schmeck, Niels Lindner, Thomas Müller, Anna Lena Andreevski, Jan Dreher, Karl Collins
  • Patent number: 11142523
    Abstract: The present invention relates to 1,3-thiazol-2-yl substituted benzamide compounds of general formula (I) as described and defined herein, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of neurogenic disorder, as a sole agent or in combination with other active ingredients.
    Type: Grant
    Filed: October 1, 2019
    Date of Patent: October 12, 2021
    Assignee: Bayer Aktiengesellschaft
    Inventors: Adam James Davenport, Nico Bräuer, Oliver Martin Fischer, Andrea Rotgeri, Antje Rottmann, Ioana Neagoe, Jens Nagel, Anne-Marie Godinho-Coelho, Jürgen Klar
  • Publication number: 20200131169
    Abstract: The present invention relates to 1,3-thiazol-2-yl substituted benzamide compounds of general formula (I) as described and defined herein, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of neurogenic disorder, as a sole agent or in combination with other active ingredients.
    Type: Application
    Filed: October 1, 2019
    Publication date: April 30, 2020
    Applicant: Bayer Aktiengesellschaft
    Inventors: Adam James DAVENPORT, Nico BRÄUER, Oliver Martin FISCHER, Andrea ROTGERI, Antje ROTTMANN, Ioana NEAGOE, Jens NAGEL, Anne-Marie GODINHO-COELHO, Jürgen KLAR
  • Publication number: 20200055842
    Abstract: The present invention covers substituted 6-(1H-pyrazol-1-yl)pyrimidin-4-amine compounds of general formula (I) as described and defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds, and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular for the treatment and/or prophylaxis of cardiovascular and renal diseases, as a sole agent or in combination with other active ingredients.
    Type: Application
    Filed: October 9, 2017
    Publication date: February 20, 2020
    Applicants: Bayer Aktiengesellschaft, Bayer Pharma Aktiengesellschaft
    Inventors: Anja GIESE, Jürgen KLAR, Alexander Helmut Michael EHRMANN, Jens WILLWACHER, David ENGEL, Andre Philippe DIESKAU, Antje KAHNERT, Alexey GROMOV, Carsten SCHMECK, Niels LINDNER, Thomas MÜLLER, Anna Lena ANDREEVSKI, Jan DREHER, Karl COLLINS
  • Patent number: 10472354
    Abstract: The present invention relates to 1,3-thiazol-2-yl substituted benzamide compounds of general formula (I) as described and defined herein, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of neurogenic disorder, as a sole agent or in combination with other active ingredients.
    Type: Grant
    Filed: November 15, 2018
    Date of Patent: November 12, 2019
    Assignee: Bayer Aktiengesellschaft
    Inventors: Adam James Davenport, Nico Bräuer, Oliver Martin Fischer, Andrea Rotgeri, Antje Rottmann, Ioana Neagoe, Jens Nagel, Anne-Marie Godinho-Coelho, Jürgen Klar
  • Publication number: 20190185466
    Abstract: The present invention relates to 1,3-thiazol-2-yl substituted benzamide compounds of general formula (I) as described and defined herein, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of neurogenic disorder, as a sole agent or in combination with other active ingredients.
    Type: Application
    Filed: November 15, 2018
    Publication date: June 20, 2019
    Applicant: Bayer Aktiengesellschaft
    Inventors: Adam James DAVENPORT, Nico BRÄUER, Oliver Martin FISCHER, Andrea ROTGERI, Antje ROTTMANN, Ioana NEAGOE, Jens NAGEL, Anne-Marie GODINHO-COELHO, Jürgen KLAR
  • Patent number: 10202369
    Abstract: The present invention relates to 1,3-thiazol-2-yl substituted benzamide compounds of general formula (I) as described and defined herein, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of neurogenic disorder, as a sole agent or in combination with other active ingredients.
    Type: Grant
    Filed: November 21, 2017
    Date of Patent: February 12, 2019
    Assignee: Bayer Aktiengesellschaft
    Inventors: Adam James Davenport, Nico Bräuer, Oliver Martin Fischer, Andrea Rotgeri, Antje Rottmann, Ioana Neagoe, Jens Nagel, Anne-Marie Godinho-Coelho, Jürgen Klar
  • Patent number: 10183932
    Abstract: The invention relates to substituted oxopyridine derivatives and to processes for their preparation, and also to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, in particular cardiovascular disorders, preferably thrombotic or thromboembolic disorders, and oedemas, and also ophthalmic disorders.
    Type: Grant
    Filed: October 17, 2017
    Date of Patent: January 22, 2019
    Assignee: Bayer Pharma Aktiengesellschaft
    Inventors: Susanne Röhrig, Alexander Hillisch, Julia Strassburger, Stefan Heitmeier, Martina Victoria Schmidt, Karl-Heinz Schlemmer, Adrian Tersteegen, Anja Buchmüller, Christoph Gerdes, Martina Schäfer, Tom Kinzel, Henrik Teller, Hartmut Schirok, Jürgen Klar, Eloisa Jimenez Nunez
  • Patent number: 10183937
    Abstract: The present invention relates to 1,3-thiazol-2-yl substituted benzamide compounds of general formula (I) as described and defined herein, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of neurogenic disorder, as a sole agent or in combination with other active ingredients.
    Type: Grant
    Filed: November 21, 2017
    Date of Patent: January 22, 2019
    Assignee: Bayer Aktiengesellschaft
    Inventors: Adam James Davenport, Nico Bräuer, Oliver Martin Fischer, Andrea Rotgeri, Antje Rottmann, Ioana Neagoe, Jens Nagel, Anne-Marie Godinho-Coelho, Jürgen Klar
  • Patent number: 10174016
    Abstract: The present invention relates to 1,3-thiazol-2-yl substituted benzamide compounds of general formula (I) as described and defined herein, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of neurogenic disorder, as a sole agent or in combination with other active ingredients.
    Type: Grant
    Filed: December 7, 2015
    Date of Patent: January 8, 2019
    Assignee: BEYER AKTIENGESELLSCHAFT
    Inventors: Adam James Davenport, Nico Bräuer, Oliver Martin Fischer, Andrea Rotgeri, Antje Rottmann, Ioana Neagoe, Jens Nagel, Anne-Marie Godinho-Coelho, Jürgen Klar
  • Patent number: 10077265
    Abstract: The invention relates to substituted oxopyridine derivatives and to processes for preparation thereof, and also to the use thereof for production of medicaments for treatment and/or prophylaxis of diseases, especially of cardiovascular disorders, preferably thrombotic or thromboembolic disorders, and oedemas, and also ophthalmic disorders.
    Type: Grant
    Filed: September 22, 2015
    Date of Patent: September 18, 2018
    Assignee: BAYER PHARMA AKTIENGESELLSCHAFT
    Inventors: Susanne Röhrig, Alexander Hillisch, Julia Straβburger, Stefan Heitmeier, Martina Victoria Schmidt, Karl-Heinz Schlemmer, Adrian Tersteegen, Anja Buchmüller, Christoph Gerdes, Martina Schäfer, Henrik Teller, Eloisa Jiménez Núnez, Hartmut Schirok, Jürgen Klar, Mario Lobell
  • Patent number: 10047096
    Abstract: The present application relates to novel (3-hydroxyphenyl)amino-substituted pyrido[2,3-b][1,5]benzodiazepin-5-one derivatives, to processes for preparation thereof, to the use thereof alone or in combination for treatment and/or prevention of diseases and to the use thereof for production of medicaments for treatment and/or prevention of diseases, especially of angiogenic disorders and hyperproliferative disorders in which neovascularization plays a role, for example ophthalmological disorders and cancers and tumours. Such treatments can be effected as monotherapy or else in combination with other medicaments or further therapeutic measures.
    Type: Grant
    Filed: November 23, 2015
    Date of Patent: August 14, 2018
    Assignee: Bayer Pharma Aktiengesellschaft
    Inventors: Andreas Schall, Jürgen Klar, Mario Lobell, Hartmut Schirok, Joachim Telser, Steffen Müller, Dirk Brohm, Hans Briem, Hannah Jörißen, Joerg Keldenich, Michael Böttger, Georges Von Degenfeld, Thomas Schlange, Ulf Bömer, Niels Lindner, Hanna Eilken, Dmitrij Hristodorov, Pierre Wasnaire, Kersten Matthias Gericke, Lars Bärfacker
  • Publication number: 20180086742
    Abstract: The invention relates to substituted oxopyridine derivatives and to processes for their preparation, and also to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, in particular cardiovascular disorders, preferably thrombotic or thromboembolic disorders, and oedemas, and also ophthalmic disorders.
    Type: Application
    Filed: October 17, 2017
    Publication date: March 29, 2018
    Inventors: Susanne RÖHRIG, Alexander HILLISCH, Julia STRASSBURGER, Stefan HEITMEIER, Martina Victoria SCHMIDT, Karl-Heinz SCHLEMMER, Adrian TERSTEEGEN, Anja BUCHMÜLLER, Christoph GERDES, Martina SCHÄFER, Tom KINZEL, Henrik TELLER, Harmut SCHIROK, Jürgen KLAR, Eloisa Jimenez NUNEZ
  • Patent number: 9822102
    Abstract: The invention relates to substituted oxopyridine derivatives and to processes for their preparation, and also to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, in particular cardiovascular disorders, preferably thrombotic or thromboembolic disorders, and oedemas, and also ophthalmic disorders.
    Type: Grant
    Filed: September 4, 2016
    Date of Patent: November 21, 2017
    Assignee: BAYER PHARMA AKTIENGESELLSCHAFT
    Inventors: Susanne Röhrig, Alexander Hillisch, Julia Strassburger, Stefan Heitmeier, Martina Victoria Schmidt, Karl-Heinz Schlemmer, Adrian Tersteegen, Anja Buchmüller, Christoph Gerdes, Martina Schäfer, Tom Kinzel, Henrik Teller, Hartmut Schirok, Jürgen Klar, Eloisa Jimenez Nunez
  • Publication number: 20170283412
    Abstract: The invention relates to substituted oxopyridine derivatives and to processes for preparation thereof, and also to the use thereof for production of medicaments for treatment and/or prophylaxis of diseases, especially of cardiovascular disorders, preferably thrombotic or thromboembolic disorders, and oedemas, and also ophthalmic disorders.
    Type: Application
    Filed: September 22, 2015
    Publication date: October 5, 2017
    Inventors: Susanne RÖHRIG, Alexander HILLISCH, Julia STRAßBURGER, Stefan HEITMEIER, Martina Victoria SCHMIDT, Karl-Heinz SCHLEMMER, Adrian TERSTEEGEN, Anja BUCHMÜLLER, Christoph GERDES, Martina SCHÄFER, Henrik TELLER, Eloisa JIMÉNEZ NÚNEZ, Hartmut SCHIROK, Jürgen KLAR, Mario LOBELL
  • Patent number: 9765070
    Abstract: The invention relates to substituted oxopyridine derivatives and to processes for their preparation, and also to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, in particular cardiovascular disorders, preferably thrombotic or thromboembolic disorders, and oedemas, and also ophthalmic disorders.
    Type: Grant
    Filed: October 28, 2014
    Date of Patent: September 19, 2017
    Assignee: BAYER PHARMA AKTIENGESELLSCHAFT
    Inventors: Susanne Röhrig, Alexander Hillisch, Julia Strassburger, Stefan Heitmeier, Martina Victoria Schmidt, Karl-Heinz Schlemmer, Adrian Tersteegen, Anja Buchmüller, Christoph Gerdes, Martina Schäfer, Henrik Teller, Eloisa Jimenez Nunez, Hartmut Schirok, Jürgen Klar
  • Publication number: 20170253602
    Abstract: The present application relates to novel (3-hydroxyphenyl)amino-substituted pyrido[2,3-b][1,5]benzodiazepin-5-one derivatives, to processes for preparation thereof, to the use thereof alone or in combination for treatment and/or prevention of diseases and to the use thereof for production of medicaments for treatment and/or prevention of diseases, especially of angiogenic disorders and hyperproliferative disorders in which neovascularization plays a role, for example ophthalmological disorders and cancers and tumours. Such treatments can be effected as monotherapy or else in combination with other medicaments or further therapeutic measures.
    Type: Application
    Filed: November 23, 2015
    Publication date: September 7, 2017
    Applicant: Bayer Pharma Aktiengesellschaft
    Inventors: Andreas SCHALL, Jürgen KLAR, Mario LOBELL, Hartmut SCHIROK, Joachim TELSER, Steffen MÜLLER, Dirk BROHM, Hans BRIEM, Hannah JÖRIßEN, Joerg KELDENICH (deceased), Michael BÖTTGER, Georges DEGENFELD VON, Thomas SCHLANGE, Ulf BÖMER, Niels LINDNER, Hanna EILKEN, Dmitrij HRISTODOROV, Pierre WASNAIRE, Kersten Matthias GERICKE, Lars BÄRFACKER